ECOG-ACRIN EA6192: A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)

Objective

This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.

https://clinicaltrials.gov/ct2/show/NCT04462406

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Studies

Specialty

• Skin Cancer

Contact

Cancer Clinical Trials at 218-786-3308
or cancertrials@essentiahealth.org